MorphoSys AG expanded its therapeutic antibody collaboration with Novartis. The original collaboration agreement provided for a three-year term with an option for Novartis to extend. The collaboration will now go through May 2011. In May 2004, the two companies forged a strategic alliance to jointly develop new antibody-based therapeutics against a range of illnesses. As part of the collaboration, Novartis invested approximately $11 million in MorphoSys. In August 2005, MorphoSys successfu...